ERBB2 and neoplasm: CAR–macrophages targeting HER2 have been demonstrated to reduce tumor growth in animal models [197,198] and are now being tested in a phase I study for HER2-expressing solid tumors in adults alone or in association with pembrolizumab (NCT04660929).